The primary objective of the present study was to perform a cost-comparison analysis betweenpre- and post-PSMA PET/CT treatment strategies in the workup of patients with biochemicalrecurrence of prostate cancer treated via the SUS. The gene discussed is FOLH1; the disease is Familial prostate cancer.